Literature DB >> 9522772

Subcutaneous apomorphine in Parkinson's disease.

K R Chaudhuri, C Clough.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9522772      PMCID： PMC1112674          DOI： 10.1136/bmj.316.7132.641

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  9 in total

Review 1.  Clinical usefulness of apomorphine in movement disorders.

Authors:  C Colosimo; M Merello; A Albanese
Journal:  Clin Neuropharmacol       Date:  1994-06       Impact factor: 1.592

2.  Apomorphine in Parkinson's disease.

Authors:  R S SCHWAB; L V AMADOR; J Y LETTVIN
Journal:  Trans Am Neurol Assoc       Date:  1951

3.  Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment.

Authors:  C Ellis; G Lemmens; J D Parkes; R J Abbott; I F Pye; P N Leigh; K R Chaudhuri
Journal:  Parkinsonism Relat Disord       Date:  1997-04       Impact factor: 4.891

4.  Similarities between neurologic effects of L-dopa and of apomorphine.

Authors:  G C Cotzias; P S Papavasiliou; C Fehling; B Kaufman; I Mena
Journal:  N Engl J Med       Date:  1970-01-01       Impact factor: 91.245

5.  Subcutaneous apomorphine in parkinsonian on-off oscillations.

Authors:  C M Stibe; A J Lees; P A Kempster; G M Stern
Journal:  Lancet       Date:  1988-02-20       Impact factor: 79.321

6.  Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.

Authors:  A J Hughes; S Bishop; B Kleedorfer; N Turjanski; W Fernandez; A J Lees; G M Stern
Journal:  Mov Disord       Date:  1993-04       Impact factor: 10.338

7.  On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.

Authors:  R J Hardie; A J Lees; G M Stern
Journal:  Brain       Date:  1984-06       Impact factor: 13.501

8.  The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys.

Authors:  R J Vermeulen; B Drukarch; M C Sahadat; C Goosen; E C Wolters; J C Stoof
Journal:  Mov Disord       Date:  1994-11       Impact factor: 10.338

9.  Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease.

Authors:  G U Corsini; M Del Zompo; G L Gessa; A Mangoni
Journal:  Lancet       Date:  1979-05-05       Impact factor: 79.321
  9 in total
  4 in total

Review 1.  Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?

Authors:  L Dépatie; S Lal
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

2.  Extra cost of subcutaneous apomorphine would pay for personal nurses.

Authors:  I Hill-Smith
Journal:  BMJ       Date:  1998-08-29

3.  Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors.

Authors:  Ajit G Thomas; Camilo Rojas; Cordelle Tanega; Min Shen; Anton Simeonov; Matthew B Boxer; Douglas S Auld; Dana V Ferraris; Takashi Tsukamoto; Barbara S Slusher
Journal:  Biochem Biophys Res Commun       Date:  2013-07-10       Impact factor: 3.575

4.  Evaluation of the Association Between Serum Levels of Testosterone and Prolactin With 6- Hydroxydopamine-Induced Parkinsonism in Male Rats.

Authors:  Roghaieh Razaghi; Hossein Piri; Hanieh Jafari; Nafiseh Rastgoo; Mohammad Ali Hosseini; Hashem Haghdoost Yazdi
Journal:  Basic Clin Neurosci       Date:  2021-07-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.